Provectus issued a PR today about Moffitt's poster presentation.
Dr. Pilon-Thomas commented, “We believe our findings are meaningful because they confirm the induction of tumor-specific immunity after single treatment with IL-PV-10 in multiple tumor types. Our data show that T cells play a crucial roll in this response, and we are continuing our work to further elucidate the mechanisms that occur following PV-10 treatment.”
Dr. Amod Sarnaik observed, “The systemic response to intralesional PV-10 treatment observed in murine models was sufficiently compelling to warrant further clinical investigation. We look forward to additional insights from our current investigational study of the immune mechanism of PV-10 ablation in cutaneous melanoma patients.”